Reference health
Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy
20/20 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 20 checked references that resolve
resolves10.1038/srep08902
Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs
resolves10.1002/hup.811
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite
resolves10.4088/JCP.v66n0614
Differences in Prolactin Elevation and Related Symptoms of Atypical Antipsychotics in Schizophrenic Patients
resolves10.1080/00926230390195524
A Survey of Sexual Side Effects Among Severely Mentally Ill Patients Taking Psychotropic Medications: Impact on Compliance
resolves10.1016/S0140-6736(13)60733-3
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
resolves10.1176/appi.ajp.2011.10111609
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
resolves10.1111/j.1440-1819.2009.02032.x
Effect of bromocriptine on antipsychotic drug‐induced hyperprolactinemia: Eight‐week randomized, single‐blind, placebo‐controlled, multicenter study
resolves10.1038/sj.npp.1301071
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
resolves10.1038/sj.npp.1300983
Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models
resolves10.4088/JCP.09m05154yel
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy
resolves10.1097/JCP.0b013e3181ee832d
Dose-Dependent Effects of Adjunctive Treatment With Aripiprazole on Hyperprolactinemia Induced by Risperidone in Female Patients With Schizophrenia
resolves10.4088/JCP.v69n0422
Antipsychotic Polypharmacy, Part 1: Shotgun Approach or Targeted Cotreatment?
resolves10.1055/s-2004-827174
High Dose Antipsychotic Use in Schizophrenia: Findings of the REAP (Research on East Asia Psychotropic Prescriptions) Study
resolves10.1016/j.pnpbp.2008.09.016
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole
resolves10.1016/j.schres.2008.09.019
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study
resolves10.1124/jpet.102.033175
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors
resolves10.1016/S0014-2999(02)01532-7
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
resolves10.1517/14740338.2016.1165668
Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials
resolves10.1016/j.jpsychires.2015.01.004
Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials
resolves10.1001/jamapsychiatry.2018.4320
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
The 2 references without a DOI — listed, not checked
no DOI — not checkedAdjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
no DOI — not checkedPhysical activity and bone health
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1097/jcp.0000000000001158"><img src="https://citestamp.com/citestamped/10.1097/jcp.0000000000001158/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1097/jcp.0000000000001158)